A novel PDX model engineered by Francis et al. [65] provides human TSLP and thus provides an important preclinical model for understanding disease mechanisms and identifying therapies that can be effective against Ph-like B-ALL with CRLF2 rearrangements. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.